HRS 5965
Alternative Names: HRS-5965Latest Information Update: 13 Feb 2026
At a glance
- Originator Chengdu Suncadia Medicine
- Class Anti-inflammatories; Small molecules; Urologics
- Mechanism of Action Complement factor B modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III IgA nephropathy; Paroxysmal nocturnal haemoglobinuria
- No development reported Glomerulonephritis
Most Recent Events
- 16 Jan 2026 Chengdu Suncadia Medicine completes a phase I trial for Kidney disorders (In Volunteers) in China (PO, Capsule) (NCT06674915)
- 06 Jan 2026 Chengdu Suncadia Medicine initiates phase III clinical trials in Paroxysmal nocturnal haemoglobinuria (Treatment-experienced) in China (PO) (NCT06715943)
- 28 Nov 2025 No recent reports of development identified for phase-I development in Glomerulonephritis(In volunteers) in China (PO, Tablet)